Anavex Life Sciences Corporation AVXL Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$1.15 up $0.04, 3.60% at close Nov 6
Last close · Previous close $1.11
- Market cap
- $106.57MAt the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$0.15Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$1.15up $0.04, 3.60%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$1.11Nov 5
- Volume1.05MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.20MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $1.07 to $7.60; now $1.15
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
AVXL trailed the S&P 500 in all 7 periods.
| Period | AVXL and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | AVXL: down 28.1% S&P 500: down 5.6% | AVXL trailed the S&P 500 by 22.5 percentage points Trailed |
| 3M | AVXL: down 64.9% S&P 500: down 4.1% | AVXL trailed the S&P 500 by 60.8 percentage points Trailed |
| YTD | AVXL: down 67.7% S&P 500: up 8.7% | AVXL trailed the S&P 500 by 76.4 percentage points Trailed |
| 1Y | AVXL: down 84.5% S&P 500: up 10.9% | AVXL trailed the S&P 500 by 95.4 percentage points Trailed |
| Long term | ||
| 3Y | AVXL: down 80.6% S&P 500: up 75.0% −42.1% vs +20.5% a year | AVXL trailed the S&P 500 by 155.6 percentage points Trailed |
| 5Y | AVXL: down 95.0% S&P 500: up 67.8% −45.1% vs +10.9% a year | AVXL trailed the S&P 500 by 162.8 percentage points Trailed |
| 10Y | AVXL: down 59.5% S&P 500: up 313.1% −8.6% vs +15.2% a year | AVXL trailed the S&P 500 by 372.6 percentage points Trailed |
$10,000 invested in AVXL 10 years ago (Nov 4, 2016) would be worth about $4,049 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
AVXL trailed the S&P 500 in all 7 periods.
| Period | AVXL and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | AVXL: down 28.1% S&P 500: down 5.6% | AVXL trailed the S&P 500 by 22.5 percentage points Trailed |
| 3M | AVXL: down 64.9% S&P 500: down 4.3% | AVXL trailed the S&P 500 by 60.6 percentage points Trailed |
| YTD | AVXL: down 67.7% S&P 500: up 7.8% | AVXL trailed the S&P 500 by 75.5 percentage points Trailed |
| 1Y | AVXL: down 84.5% S&P 500: up 9.7% | AVXL trailed the S&P 500 by 94.2 percentage points Trailed |
| Long term | ||
| 3Y | AVXL: down 80.6% S&P 500: up 68.8% −42.1% vs +19.1% a year | AVXL trailed the S&P 500 by 149.4 percentage points Trailed |
| 5Y | AVXL: down 95.0% S&P 500: up 56.9% −45.1% vs +9.4% a year | AVXL trailed the S&P 500 by 151.9 percentage points Trailed |
| 10Y | AVXL: down 59.5% S&P 500: up 252.6% −8.6% vs +13.4% a year | AVXL trailed the S&P 500 by 312.1 percentage points Trailed |
$10,000 invested in AVXL 10 years ago (Nov 4, 2016) would be worth about $4,049 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$28.86
Closing high on . Now 96.0% below that record.
Split-adjusted daily closes since Aug 2, 2006.
Stock splits
1
1-for-4 on . Share counts adjust after each split.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$0.15 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. How to read P/E
Other valuation measures
- 0.9×Book value as of Jun 30, 2026
Price relative to accounting equity (book value) per share on the Jun 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - −27.48%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - −$11.75MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own AVXL DCF in Excel. Value Anavex Life Sciences with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$13.02M
- Diluted EPS
- −$0.15
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Sep 30, 2024) | $0.00 | −$11.62M | −$0.14 |
| Q1 FY25 (Dec 31, 2024) | $0.00 | −$12.11M | −$0.14 |
| Q2 FY25 (Mar 31, 2025) | $0.00 | −$11.20M | −$0.13 |
| Q3 FY25 (Jun 30, 2025) | $0.00 | −$13.24M | −$0.16 |
| Q4 FY25 (Sep 30, 2025) | $0.00 | −$9.83M | −$0.11 |
| Q1 FY26 (Dec 31, 2025) | $0.00 | −$5.68M | −$0.06 |
| Q2 FY26 (Mar 31, 2026) | $0.00 | −$5.34M | −$0.06 |
| Q3 FY26 (Jun 30, 2026) | $0.00 | $7.82M | $0.08 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Sep 30, 2021) | $0.00 | −$37.91M | −$0.54 |
| FY22 (Sep 30, 2022) | $0.00 | −$47.98M | −$0.62 |
| FY23 (Sep 30, 2023) | $0.00 | −$47.51M | −$0.60 |
| FY24 (Sep 30, 2024) | $0.00 | −$43.00M | −$0.52 |
| FY25 (Sep 30, 2025) | $0.00 | −$46.38M | −$0.54 |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$29.29MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$29.29MLast 12 months
- Capital spending$0.00Last 12 months
Shareholder returns
- $46.90MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $118.33MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$0.00As of Jun 30, 2026
- Net cash$118.33MAs of Jun 30, 2026
- 15.62As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −11.4%Last 12 months
Over the last 12 months, Anavex Life Sciences lost money: its net loss was 11.4% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −10.7%Last 12 months
Over the last 12 months, Anavex Life Sciences’s net loss was 10.7% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Anavex Life Sciences Corporation
Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 ( blarcamesine ), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New York, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
AVXL news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
AVXL stock FAQ
What is AVXL stock’s price today?
Anavex Life Sciences (AVXL) traded at $1.15 at the close on , up $0.04 (3.60%) from the previous close of $1.11. Over the past 52 weeks it has traded between $1.07 and $7.60.
If you invested $1,000 in AVXL 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in AVXL on would be worth about $405 at the close on , a total return of −59.5%. The same $1,000 would be worth $50 if invested five years ago, $155 if invested one year ago, and $113 if invested 20 years ago. Past performance doesn’t predict future returns.
What is Anavex Life Sciences’s market cap?
Anavex Life Sciences’s market capitalization is about $106.6 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $1.15 (how market cap works). Anavex Life Sciences reported 92.67M shares outstanding at the end of its latest quarter ().
What is AVXL’s P/E ratio?
AVXL’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$0.15).
What are AVXL’s earnings per share?
AVXL’s diluted earnings per share were −$0.15 over the four quarters to , compared with −$0.57 in the twelve months before. The latest quarter (Q3 FY26) brought $0.08 per share, against −$0.16 a year earlier (how EPS works).
Does AVXL pay a dividend?
Anavex Life Sciences hasn’t paid a dividend in the last twelve months.
What is AVXL’s 52-week high and low?
Over the past 52 weeks AVXL has traded as low as $1.07 and as high as $7.60. At $1.15 at the close on , it is 84.9% below that high and 8.0% above the low.
What is AVXL’s all-time high?
AVXL’s highest closing price was $28.86 on , adjusted for stock splits. At $1.15 at the close on , it is 96.0% below that record.
Has AVXL stock ever split?
Yes, once: 1-for-4 on .
How has AVXL stock performed?
Including dividends and measured to the close on , AVXL has returned −67.7% so far this year and −84.5% over the past year, and −95.0% over five years (−45.1% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Anavex Life Sciences in?
Anavex Life Sciences is in the Healthcare sector and the Biotechnology industry, and is headquartered in New York, USA.
What exchange does AVXL trade on?
Anavex Life Sciences trades on the Nasdaq under the ticker symbol AVXL. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.